RxDoctor Payments Data

Elizabeth Pagler, MD

Family Medicine · Rancho Cucamonga, CANPI 1295185254

Payments from drug & device makers

$1,792in general payments, 2019–2025

Across 81 payments — averaging $22.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$354
  • Lilly USA, LLC$291
  • Novo Nordisk$223
  • Amgen$190
  • AstraZeneca$135
  • Bayer$102
  • plus $497 from 13 others

What the payments were for

  • Food & beverage$1,792100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,792 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$8,410
Medicare patients
24
Services billed
78

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide188$179,766
EliquisApixaban64$77,858
TrulicityDulaglutide67$74,963
MounjaroTirzepatide61$74,718
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$51,622
JardianceEmpagliflozin33$46,387
Repatha SureclickEvolocumab40$33,356
XareltoRivaroxaban27$18,999
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$16,689
FarxigaDapagliflozin Propanediol16$11,467
Breo ElliptaFluticasone/Vilanterol21$9,061
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$6,247
Atorvastatin Calcium553$5,466
MyrbetriqMirabegron12$4,935
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$4,479

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$223$179,766188 claims
Lilly USA, LLCTrulicity, Mounjaro$291$149,680128 claims
PfizerEliquis$85$77,85864 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$36$77,371103 claims
Johnson & JohnsonXarelto$14$18,99927 claims
AstraZenecaFarxiga$135$11,46716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Rancho Cucamonga

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →